Review of rabeprazole in the treatment of gastro-oesophageal reflux disease
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationExpert Opin Pharmacother 2004, 5(1):137-49
AbstractGastro-oesophageal reflux disease (GERD) is an increasing health problem in developed countries and is associated with enormous costs in terms of reduced quality of life, loss of productivity, health expenses and mortality. The gastrointestinal disease with the highest annual direct costs in the US (in the year 2000) was GERD (9.3 billion US dollars). GERD is primarily a motility disorder of the oesophagus, however, there are no available promotility drugs on the market. The main symptoms are heartburn and acid regurgitation arising from the reflux of gastric acid, which is the only factor at present suited for pharmacological intervention. The proton pump inhibitors (PPIs) give optimal benefit in the treatment of GERD. The sales of PPIs in the year 2002 amounted to 12 billion US dollars in North America and 4 billion US dollars in Europe and the sales have been increasing by > 10% annually. This paper reviews the use of PPIs in the treatment of GERD with particular focus on one of the newer agents, rabeprazole.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Link field
- Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
- Authors: Wit NJ, Boer WA, Geldof H, Hazelhoff B, Bergmans P, Tytgat GN, Smout AJ
- Issue date: 2004 Aug 15
- Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
- Authors: Miner P
- Issue date: 2004 Nov
- Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.
- Authors: Galmiche JP, Zerbib F, Ducrottè P, Fournet J, Rampal P, Avasthy N, Humphries TJ
- Issue date: 2001 Sep
- Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
- Authors: Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ
- Issue date: 1999 Jan
- Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
- Authors: Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L, FAST Trial Investigators.
- Issue date: 2002 Mar